Literature DB >> 14736800

Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension.

C S Marsh, B Marden, R Newsom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14736800      PMCID： PMC1772024          DOI： 10.1136/bjo.2003.021956

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  5 in total

1.  Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension.

Authors:  D Abrams; I Schulze-Neick; A G Magee
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

2.  Sildenafil (Viagra) a cause of proliferative diabetic retinopathy?

Authors:  A J Burton; A Reynolds; D O'Neill
Journal:  Eye (Lond)       Date:  2000-10       Impact factor: 3.775

3.  Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension.

Authors:  Lara S Shekerdemian; Hanne B Ravn; Daniel J Penny
Journal:  Am J Respir Crit Care Med       Date:  2002-04-15       Impact factor: 21.405

4.  Effect of sildenafil citrate (Viagra) on the ocular circulation.

Authors:  J E Grunwald; K K Siu; S S Jacob; J Dupont
Journal:  Am J Ophthalmol       Date:  2001-06       Impact factor: 5.258

5.  Sildenafil increases ocular perfusion.

Authors:  G Paris; W E Sponsel; S S Sandoval; W R Elliott; Y Trigo; D K Sanford; J M Harison
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031
  5 in total
  16 in total

Review 1.  Sildenafil for pulmonary hypertension in neonates.

Authors:  Lauren E Kelly; Arne Ohlsson; Prakeshkumar S Shah
Journal:  Cochrane Database Syst Rev       Date:  2017-08-04

2.  No evidence for severe retinopathy of prematurity following sildenafil.

Authors:  C M Pierce; A J Petros; A R Fielder
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

Review 3.  Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension.

Authors:  Leah Leibovitch; Ilan Matok; Gideon Paret
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Sildenafil for the Treatment of Pulmonary Arterial Hypertension in Infants with Bronchopulmonary Dysplasia.

Authors:  M N Trottier-Boucher; A Lapointe; J Malo; A Fournier; M J Raboisson; B Martin; A Moussa
Journal:  Pediatr Cardiol       Date:  2015-04-01       Impact factor: 1.655

Review 5.  Controversies in the identification and management of acute pulmonary hypertension in preterm neonates.

Authors:  Regan E Giesinger; Kiran More; Jodie Odame; Amish Jain; Robert P Jankov; Patrick J McNamara
Journal:  Pediatr Res       Date:  2017-10-04       Impact factor: 3.756

Review 6.  Retinopathy of prematurity: a review of risk factors and their clinical significance.

Authors:  Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang
Journal:  Surv Ophthalmol       Date:  2018-04-19       Impact factor: 6.048

7.  Effect of a phosphodiesterase 5 inhibitor on pulmonary and cerebral arteries of newborn piglets with chronic hypoxia-induced pulmonary hypertension.

Authors:  Candice D Fike; Mark Kaplowitz; Yongmei Zhang; Mark Dantuma; Jane A Madden
Journal:  Neonatology       Date:  2011-07-26       Impact factor: 4.035

Review 8.  Safety of sildenafil in infants*.

Authors:  Samira Samiee-Zafarghandy; P Brian Smith; Johannes N van den Anker
Journal:  Pediatr Crit Care Med       Date:  2014-05       Impact factor: 3.624

Review 9.  Sildenafil for the treatment of pulmonary hypertension in pediatric patients.

Authors:  Alice J Huddleston; Chad A Knoderer; Jennifer L Morris; Eric S Ebenroth
Journal:  Pediatr Cardiol       Date:  2009-08-25       Impact factor: 1.655

10.  Sildenafil attenuates vaso-obliteration and neovascularization in a mouse model of retinopathy of prematurity.

Authors:  Amani A Fawzi; Jonathan C Chou; Gina A Kim; Stuart D Rollins; Joann M Taylor; Kathryn N Farrow
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-10       Impact factor: 4.799
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.